法布雷病患者心脏MRI左心室肥厚与晚期钆增强与不良心脏事件相关
回顾性纳入90例基因阳性法布雷病患者,评估心脏MRI表现对不良心脏复合终点的预后价值。中位随访3.6年,21例达到复合终点;左心室肥厚(HR 3.0)和晚期钆增强(HR 7.2)为独立预测因子,广泛晚期钆增强(≥15%左心室质量)风险最高(HR 12)。
要点
- 左心室肥厚和晚期钆增强是法布雷病不良心脏事件的独立预测因子。
- 广泛晚期钆增强(≥15%左心室质量)患者风险最高,HR为12。
- 性别不改变心脏MRI参数与复合终点之间的关系。
核心结论
- 心脏MRI左心室肥厚和晚期钆增强可用于识别法布雷病中不良心脏事件高风险患者。
研究设计与样本
- 回顾性队列研究,纳入2008年3月至2019年1月在一家大型三级转诊医院连续行心脏MRI的基因阳性法布雷病女性与男性患者,共90例(平均年龄44岁±15[标准差],59例女性)。
- 心脏MRI评估者对全部临床信息设盲,参考标准为复合终点(室性心动过速、需植入装置的严重心动过缓、重度心力衰竭和心源性死亡)。
- 统计分析采用校正年龄和Mainz严重程度评分指数(法布雷病严重程度指标)的Cox比例风险模型。
关键影像表现/征象
- 心脏MRI显示左心室肥厚和晚期钆增强,二者均为复合终点的独立预测因子。
- 晚期钆增强范围≥15%左心室质量的患者风险最高。
诊断标准与关键数值
- 左心室肥厚预测复合终点:HR 3.0(95%CI 1.1,8.1;P=.03)。
- 晚期钆增强预测复合终点:HR 7.2(95%CI 1.5,34;P=.01)。
- 广泛晚期钆增强(≥15%左心室质量)预测复合终点:HR 12(95%CI 2.0,67;P=.006)。
- 性别与左心室肥厚的交互作用P=.15,与晚期钆增强的交互作用P=.38,性别不修饰上述关系。
临床应用与阅片要点
- 阅读法布雷病心脏MRI时,应评估左心室肥厚和晚期钆增强,并注意晚期钆增强范围是否≥15%左心室质量,以提示不良心脏事件风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Cardiac involvement is the leading cause of mortality in patients with Fabry disease. Identification of imaging findings that predict adverse cardiac events is needed to enable identification of high-risk patients. Purpose To establish the prognostic value of cardiac MRI findings in men and women with Fabry disease. Materials and Methods Consecutive women and men with gene-positive Fabry disease who had undergone cardiac MRI at a single large tertiary referral hospital between March 2008 and January 2019 were included in this retrospective cohort study. Evaluators of cardiac MRI studies were blinded to all clinical information. Adverse cardiac events were assessed as a composite end point, defined as ventricular tachycardia, bradycardia requiring device implantation, severe heart failure, and cardiac death. Statistical analysis included Cox proportional hazard models adjusted for age and Mainz Severity Score Index (a measure of the severity of Fabry disease). Results Ninety patients (mean age, 44 years ± 15 [standard deviation]; 59 women) were evaluated. After a median follow-up period of 3.6 years, the composite end point was reached in 21 patients (incidence rate, 7.6% per year). Left ventricular hypertrophy (LVH) and late gadolinium enhancement (LGE) were independent predictors of the composite end point in adjusted analysis (LVH hazard ratio [HR], 3.0; 95% confidence interval [CI]: 1.1, 8.1; P = .03; and LGE HR, 7.2; 95% CI: 1.5, 34; P = .01). Patients with extensive LGE (≥15% of left ventricular mass) were at highest risk (HR, 12; 95% CI: 2.0, 67; P = .006). Sex did not modify the relationship between the composite end point and any of the cardiac MRI parameters, including LVH (P = .15 for interaction term) and LGE (P = .38 for interaction term). Conclusion Cardiac MRI findings of left ventricular hypertrophy and late gadolinium enhancement can be used to identify patients with Fabry disease who are at high risk of adverse cardiac events. © RSNA, 2019 See also the editorial by Zimmerman in this issue.
引用
- Hanneman K, Karur GR, Wasim S, et al. Left Ventricular Hypertrophy and Late Gadolinium Enhancement at Cardiac MRI Are Associated with Adverse Cardiac Events in Fabry Disease. Radiology. 2019. PMID: 31660802. doi:10.1148/radiol.2019191385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。